Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: A retrospective study on behalf of the EBMT pediatric diseases working party

Bone Marrow Transplantation

Volumn 46, Issue 12, 2011, Pages 1510-1518

  Wachowiak, J ^a   Sykora, K W ^b   Cornish, J ^b   Chybicka, A ^b   Kowalczyk, J R ^b   Gorczyska, E ^b   Choma, M ^b   Grund, G ^a   Peters, C ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Department of Pediatric Hematology/Oncology ^*  (Poland)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

allogeneic hematopoietic SCT; childhood hematological malignancies; preparative regimen; Treosulfan

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; MELPHALAN; MEPREDNISONE; METHOTREXATE; MYCOPHENOLIC ACID; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; ADOLESCENT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AORTA THROMBOSIS; ARTICLE; BLADDER DISEASE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD CANCER; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INFANT; INVASIVE ASPERGILLOSIS; LIVER TOXICITY; LUNG INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; ORAL MUCOSAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SINGLE DRUG DOSE; STOMATITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR ENGRAFTMENT;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CARMUSTINE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MELPHALAN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84856113386     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.343     Document Type: Article

References (50)

1. Miano M, Faraci M, Dini G, Bordigoni P. Early complications following haematopoietic SCT in children. Bone Marrow Transplant 2008; 41(Suppl 2): S39-S49.
2. Ranke MB, Schwarze CP, Dopfer R, Klingebiel T, Scheel-Walter HG, Lang P et al. Late effects after stem cell transplantation (SCT) in children-growth and hormones. Bone Marrow Transplant 2005; 35(Suppl 1): S77-S81. (Pubitemid 40613929)
3. Ortega JJ, OlivéT, de Heredia CD, Llort A. Secondary malignancies and quality of life after stem cell transplantation. Bone Marrow Transplant 2005; 35(Suppl 1): S83-S87. (Pubitemid 40613930)
4. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies; What have we learned over the last 10 years? In: Berliner N, Lee SJ, Linenberger M, Vogelsang GB (eds). Hematology 2005. ASH Education Program Book, ASH: Washington, DC, USA, 2005 pp 384-389.
5. Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid Bradley M, George D et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622. (Pubitemid 38455923)
6. Casper J, Wilhelm S, Steiner B, Hammer U, Hanner U, Wegener R, Freund M. Treosulfan and fludarabine conditioning for allogeneic blood stem cell transplantation. Bone Marrow Transplant 2000; 25(Suppl 1): S129 (abstract 377).
7. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725-731. (Pubitemid 38140111)
8. Feit PW, Rastrup-Andersen N. Studies in epoxide formation from (2S, 3S)-threitol-1, 4-bismethan sulfonate. The preparation and biological activity of (2S, 3S)-1, 2-epoxy-3, 4-butanediol-4-methansulfonate. J Med Chem 1970; 13: 1173-1175.
9. Fichtner I, Becker M, Baumgart J. Antileukemic activity of treosulfan in xenografted human acute lymphoblastic leukemias (ALL). Eur J Cancer 2003; 39: 801-807. (Pubitemid 36315997)
10. Schmidmaier R, Oellereich M, Baumgart J, Emmerich B, Meinhardt G. Treosulfan induced apoptosis in AML cells is accompanied by translocation of PKC delta and enhanced by bryostatin-1. Exp Hematol 2004; 32: 76-86. (Pubitemid 38064404)
11. Topaly J, Fruehauf S, Ho AD, Zeller WJ. Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: implication for pretransplant conditioning. Br J Cancer 2002; 86: 1487-1493. (Pubitemid 34548074)
12. Munkelt D, Koehl U, Kloess S, Zimmermann S-Y, El Kalaa R, Wehner S et al. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemotherapy Pharmacol 2008; 62: 821-830.
13. Lanvers-Kaminsky C, Bremer A, Dirksen U, Jürgens H, Boos J. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 2006; 17: 657-662. (Pubitemid 44265866)
14. Ploemacher RE, Westerhof GR, Blokland I, Baumgart J, Down JD. Treosulfan as an alternative conditioning agent in bone marrow transplantation. Bone Marrow Transplant 2000; 25(Suppl 1): S141 (abstract 421).
15. Westerhof GR, Pleomacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470-5478.
16. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216.
17. Glowka FK, Karazniewicz-Lada M, Grund G, Wrobel T, Wachowiak J. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant 2008; 42(Suppl 2): S67-S70.
18. Harstrick A, Wilke H, Eberhardt W. Phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153-156. (Pubitemid 26182874)
19. Wachowiak J, Chybicka A, Boruczkowski D, Gorczynska E, Kalwak K, Leda M et al. Intravenous treosulfan in conditioning before allogeneic HSCT from MSD in children with high risk of toxic complications related to conventional preparative regimen. Bone Marrow Transplant 2002; 30(Suppl 1): S12. (abstract 16).
20. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestatios of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.
21. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host disease syndrome in man. A long term clinical pathological study of 20 Seattle patients. Am J Med 1980; 69: 204-212.
22. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568. (Pubitemid 19092391)
23. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
24. Beelen DW, Trenschel R, Casper J, Freund M, Hilgar RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005; 35: 233-241. (Pubitemid 40268293)
25. Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acte myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 2006; 37: 339-344. (Pubitemid 43250466)
26. Besinger WI, Spielberger R. Preparative regimens and modification of regimen related toxicities. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing Ltd: Malden, MA, 2004, pp 158-177.
27. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231-234.
28. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002; 22: 27-42.
29. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746-750.
30. Barker CC, Butzer JD, Anderson RA, Brant R, Sauve RS. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003; 32: 79-87. (Pubitemid 36850284)
31. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404. (Pubitemid 41503656)
32. Michel G, Valteau-Couanet D, Esperou H, Gentet JC, Doz F, Méchinaud F et al. A new i.v. busulfan fixed dosing for conditioning before autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in children with malignant and non-malignant diseases : pharmacokinetics, toxicity and clinical outcomes. Blood 2005; 106: 500a (abstract 1758).
33. Vassal G, Deroussent A, Hartmann O, Challines D, Benhamon E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207. (Pubitemid 20323675)
34. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476. (Pubitemid 35174820)
35. Stein G, Dini G, Yaniv I. The hope and the reality of reduced intensity transplants in children with malignant diseases. Bone Marrow Transplant 2005; 35(Suppl 1): S39-S43. (Pubitemid 40613921)
36. Satwani P, Harrison L, Morris E, Del Toro R, Cairo MA. Reduced-intensity allogeneic stem cell transplantation in adults and in children with malignant and non-malignant diseases. Biol Blood Marrow Transplant 2005; 11: 403-422. (Pubitemid 40753793)
37. Jacobsohn DA, Duerst R, Tse W, Ketzel M. Reduced intensity hematopoietic stem cell transplantation for treatment of nonmalignant diseases in children. Lancet 2004; 364: 156-162. (Pubitemid 38891687)
38. Horn B, Baxter-Lowe L-A, Englert L, McMillan A, Quinn M, Desantes K, Cowan M. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006; 37: 263-269.
39. Valcárcel D, Martino R, Caballero D, Mateos VM, Perez-Simon JA, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003; 31: 387-392. (Pubitemid 36410685)
40. Cwynarski K, Roberts IAG, Iacobelli S, vanBiazen A, Brand R, Devergie A et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003; 102: 1224-1231. (Pubitemid 36988026)
41. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remisson given hematopoietic stem cell transplantation from unrelated donor. Leukemia 2002; 16: 2228-2237. (Pubitemid 35331838)
42. Ortega JJ, Diaz de Heredia C, OlivéT, Bastida P, Llort A, Armadans L et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica 2003; 88: 290-299. (Pubitemid 36358717)
43. Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419.
44. Satwani P, Sather H, Ozkaynak F, Heerema NA, Schultz KR, Sanders J et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a children's oncology group study report. Biol Blood Marrow Transplant 2007; 13: 218-227. (Pubitemid 46112371)
45. Matthes-Martin S, Lamche M, Ladenstein R, Eminger W, Felsberg C, Topf R et al. Organ toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single centre retrospective analysis. Bone Marrow Transplant 1999; 23: 1049-1053. (Pubitemid 29250851)
46. Nemecek ER, Gooley TA, Woolfrey AE, Carpenter PA, Mattwes DC, Sanders JE. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 2004; 34: 799-806. (Pubitemid 39467892)
47. Munoz A, Badell I, Olive T, Verdeguer A, Gomez P, Buero E. Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of GETMON overall survival and long-term follow up. Haematologica 2002; 87: 331-332. (Pubitemid 34212456)
48. Shah A-J, Kapoor N, Weinberg KI, Crooks GM, Kohn DB, Lemarsky C et al. Second hematopoietic stem cell transplantation in pediatric patients: overall survival and long-term follow up. Biol Blood Marrow Transplant 2002; 8: 221-228. (Pubitemid 34520537)
49. Wachowiak J, Bettoni C, Lange A, Malicki J, Kaczmarek-Kanold M, G"uszak B et al. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia ? Acta Haematol Pol 1995; 26: 377-384. (Pubitemid 26112842)
50. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003; 32: 543-548. (Pubitemid 37203324)